Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study.
about
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best PracticeBiomarkers in chronic kidney disease, from kidney function to kidney damagePerformance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney DiseaseAutosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Interplay between Diagnostic Criteria and Prognostic Accuracy in Chronic Kidney Disease.Uremic Solutes in Chronic Kidney Disease and Their Role in ProgressionIohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure.Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney diseaseNovel Biomarkers for Renal Diseases? None for the Moment (but One).Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?Diagnostic Evaluation as a Biomarker in Patients with ADPKD.ADPKD: clinical issues before and after renal transplantation.Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations.
P2860
Q26767011-FA9299D7-0680-4573-8008-772A4FD508EDQ28087304-590A4AF3-4AFA-4887-BF6C-30722E2F22EEQ33873062-B991F3E0-C0C5-4C5E-951A-5E196692FAEBQ34467747-7B19DD5A-5D9D-4C5B-919B-1643D2FE96D4Q36138121-956C25B6-DF43-48D9-9064-615B6885F4D2Q36235662-0AB111AA-3527-4FCC-A55A-7647FBF049F8Q36453374-E0E5BB34-4A39-4145-ACB6-A6F868FE6818Q36874564-5026DFD1-9E8F-4330-B1CD-E68F3633D3C7Q37219039-BB8F1EB9-D95E-428A-BB41-1158EF0251D2Q38763898-F1AF0612-A77B-4ADF-89D8-FB400231A34DQ38966669-5B23F5CF-62D6-4BB3-B318-3BC605E65ECDQ38978474-ED3221C2-7379-45E4-8260-0DF8E192D642Q38987102-FDD4A38F-06CE-4FAA-B4EB-319DD9C426BDQ47705916-78E6D40F-459C-4882-B1D8-95513E81A414Q50048323-E372FC37-E6AE-4F3D-9602-F47AA19B8FFB
P2860
Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Measuring and estimating GFR a ...... f a longitudinal cohort study.
@ast
Measuring and estimating GFR a ...... f a longitudinal cohort study.
@en
Measuring and estimating GFR a ...... f a longitudinal cohort study.
@nl
type
label
Measuring and estimating GFR a ...... f a longitudinal cohort study.
@ast
Measuring and estimating GFR a ...... f a longitudinal cohort study.
@en
Measuring and estimating GFR a ...... f a longitudinal cohort study.
@nl
prefLabel
Measuring and estimating GFR a ...... f a longitudinal cohort study.
@ast
Measuring and estimating GFR a ...... f a longitudinal cohort study.
@en
Measuring and estimating GFR a ...... f a longitudinal cohort study.
@nl
P2093
P2860
P50
P1433
P1476
Measuring and estimating GFR a ...... f a longitudinal cohort study.
@en
P2093
Antonio Cannata
Erasmo Buongiorno
Fabiola Carrara
Flavio Gaspari
GFR-ADPKD Study Group
Mauro Dugo
Nadia Stucchi
Norberto Perico
Olimpia Diadei
Patrizia Ondei
P2860
P304
P356
10.1371/JOURNAL.PONE.0032533
P407
P577
2012-02-28T00:00:00Z